Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer.

Authors

Jonathan J Hue
Katherine Bingmer
Kavin Sugumar
Sarah C Markt
Luke D Rothermel
Jeffrey M Hardacre
John B Ammori
Jordan M Winter
Lee Ocuin MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

1-1-2021

Volume

7

Issue

1

First Page

31

Last Page

38

ISSN

2475-3246

Published In/Presented At

Hue, J. J., Bingmer, K., Sugumar, K., Markt, S. C., Rothermel, L. D., Hardacre, J. M., Ammori, J. B., Winter, J. M., & Ocuin, L. M. (2021). Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Journal of pancreatic cancer, 7(1), 31–38. https://doi.org/10.1089/pancan.2021.0003

Disciplines

Medicine and Health Sciences

PubMedID

33937617

Department(s)

Department of Surgery, Lehigh Valley Topper Cancer Institute

Document Type

Article